Understanding how certain antibodies neutralize HIV-1
Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1
This study is looking at special antibodies that can help fight HIV-1 by targeting its protective sugar coating, with the goal of finding better treatments or vaccines for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10911130 on NIH RePORTER |
What this research studies
This research investigates the structural characteristics of antibodies that can effectively neutralize HIV-1 by targeting its glycan shield. The study focuses on a specific type of antibody known as Fab-dimerized glycan-reactive antibodies, which have unique structural properties that enhance their ability to bind to multiple glycans on the HIV-1 envelope. By examining how these antibodies interact with the virus, researchers aim to uncover the mechanisms behind their effectiveness and improve our understanding of B cell responses to glycan targets. This knowledge could lead to the development of more effective treatments or vaccines against HIV-1.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV-1 who may benefit from new therapeutic approaches targeting the virus's glycan shield.
Not a fit: Patients who are not infected with HIV-1 or those with other unrelated health conditions may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective therapies or vaccines for HIV-1, potentially improving outcomes for patients living with the virus.
How similar studies have performed: Other research has shown promise in understanding antibody interactions with viral glycan shields, indicating that this approach could yield significant insights.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Acharya, Priyamvada — Duke University
- Study coordinator: Acharya, Priyamvada
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.